---
title: "US IPO Weekly Recap: Anthropic files for potentially record-breaking IPO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303808971.md"
description: "Anthropic filed for a potentially record-breaking IPO, estimated to raise over $75 billion. Other notable activity included OPay pricing at the low end of its range to raise $304 million, while biotechs Bambusa Therapeutics and Aspen Neuroscience priced their offerings at midpoints and lows respectively. Georgia Banking Company completed a direct listing on Nasdaq, trading 27.9% above its private round price. The Renaissance IPO Index rose 11.1% year-to-date."
datetime: "2026-10-30T22:25:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303808971.md)
  - [en](https://longbridge.com/en/news/303808971.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303808971.md)
generator: "portal-rs"
---

# US IPO Weekly Recap: Anthropic files for potentially record-breaking IPO

Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. However, the week’s most notable news came from **Anthropic** (ANT), which filed its long awaited S-1 on Monday for an IPO that could be the largest ever.

Nigeria-focused fintech **OPay** (OPAY) priced at the low end of the range to raise $304 million at a $4.0 billion market cap. Cornerstone investors committed to nearly 90% of the offering, with Standard Bank kicking in up to an additional $200 million in a private placement. OPay boasts that it is the #1 finance app in Africa and the Middle East based on MAUs, offering digital wallets, debit cards, savings products, and peer-to-peer and merchant payments. It is the latest in a string of Africa-linked IPOs; however, in a highly unusual case, OPay unexpectedly did not begin trading on Friday.

Immunology and inflammation biotech **Bambusa Therapeutics** (BBTX) priced its upsized IPO at the midpoint to raise $169 million at an $856 million market cap. A developer of long-acting bispecific antibodies, Bambusa’s lead candidate, BBT001, targets IL-4Rα and IL-31. It is in Phase 1 trials for atopic dermatitis, where it reported initial proof-of-concept data in July 2026, and has an ongoing Phase 2a trial in China for chronic spontaneous urticaria. Bambusa Therapeutics finished the week down 6.3%.

Parkinson’s disease biotech **Aspen Neuroscience** (ASPE) priced at the low end of the range to raise $141 million at a $462 million market cap. Aspen is developing autologous induced pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases. Its lead candidate, sasineprocel, is a single-dose cell therapy made from cells taken from a patient’s own skin biopsy, designed to replace the dopaminergic neurons lost in Parkinson’s disease. Aspen Neuroscience finished the week down 0.7%.

Atlanta area bank **Georgia Banking Company** (GBC) completed its direct listing on the Nasdaq. Backed by Patriot Financial Partners, Fortress Investment Group, and AllianceBernstein, the company provides a variety of commercial and community banking services in the Atlanta area through 10 full-service banking offices and three loan production offices. It finished the week at $38.38, or 27.9% above its last private round of $30.

Four IPOs submitted initial filings this week, headlined by AI model developer **Anthropic**. We estimate that it could raise $75 billion or more in a mid-November listing, potentially eclipsing SpaceX as the largest IPO ever. After filing an initial prospectus, the company must wait 15 days before publicly marketing the deal, meaning investors will have to wait at least one more week before seeing the roadshow. In the meantime, Anthropic could submit an amended filing detailing its highly anticipated third quarter results.

**IPO Market Snapshot**  
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/29/2026, the Renaissance IPO Index was up 11.1% year-to-date, while the S&P 500 was up 13.8%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Astera Labs (ALAB) and SpaceX (SPCX). The Renaissance International IPO Index was up 12.6% year-to-date, while the ACWX was up 12.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Galderma and Kioxia (Toshiba Memory).

### Related Stocks

- [ANT.US](https://longbridge.com/en/quote/ANT.US.md)
- [ASPE.US](https://longbridge.com/en/quote/ASPE.US.md)
- [BBTX.US](https://longbridge.com/en/quote/BBTX.US.md)
- [GBC.US](https://longbridge.com/en/quote/GBC.US.md)
- [OPAY.US](https://longbridge.com/en/quote/OPAY.US.md)

## Related News & Research

- [How to interpret Anthropic's IPO pricing in the pre-IPO perpetual contract market?](https://longbridge.com/en/news/305100842.md)
- [Anthropic IPO guide: Everything you need to know](https://longbridge.com/en/news/305691440.md)
- [Anthropic’s Valuation Target Has Slipped From $2 Trillion to Under $1.5 Trillion. Here’s Why](https://longbridge.com/en/news/305493732.md)
- [Anthropic's IPO is about six times oversubscribed, Bloomberg News reports](https://longbridge.com/en/news/305371908.md)
- [Anthropic's IPO roadshow kicks off - and the big money is already lining up](https://longbridge.com/en/news/305192625.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**